相似文献
1
When Should Therapy for Inflammatory Bowel Disease Be Stopped?
Gastroenterol Hepatol (N Y). 2015 Jun;11(6):400-2.
2
Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial.
Aliment Pharmacol Ther. 2017 Jul;46(2):142-149. doi: 10.1111/apt.14106. Epub 2017 Apr 27.
3
[Aphthous mouth ulcers as an initial manifestation of sécukinumab-induced inflammatory bowel disease].
Ann Dermatol Venereol. 2018 Nov;145(11):676-682. doi: 10.1016/j.annder.2018.07.009. Epub 2018 Oct 23.
4
Concomitant Therapy with Immunomodulator Enhances Infliximab Durability in Pediatric Inflammatory Bowel Disease.
Inflamm Bowel Dis. 2017 Oct;23(10):1762-1773. doi: 10.1097/MIB.0000000000001212.
5
[Pregnancy outcome in inflammatory bowel diseases].
Gastroenterol Clin Biol. 1999 May;23(5):464-9.
6
[Frequency of serious adverse events of thiopurine treatment in normal thiopurine S-methyltransferase genotype children with inflammatory bowel disease].
Orv Hetil. 2019 Feb;160(5):179-185. doi: 10.1556/650.2019.31277.
7
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.
Aliment Pharmacol Ther. 2018 Mar;47(6):753-762. doi: 10.1111/apt.14525. Epub 2018 Jan 29.
8
Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease).
Hepatogastroenterology. 1998 May-Jun;45(21):691-9.
9
Semen Quality and Sperm DNA Integrity in Patients With Severe Active Inflammatory Bowel Disease and Effects of Tumour Necrosis Factor-alpha Inhibitors.
J Crohns Colitis. 2019 Apr 26;13(5):564-571. doi: 10.1093/ecco-jcc/jjy198.
10
Effect of psychological therapy on disease activity, psychological comorbidity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis.
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):189-199. doi: 10.1016/S2468-1253(16)30206-0. Epub 2017 Jan 18.
引用本文的文献
1
A Whole Food Plant-Based Approach to Ulcerative Colitis; A Case Series.
Am J Lifestyle Med. 2023 Nov 9;18(2):189-195. doi: 10.1177/15598276231213325. eCollection 2024 Mar-Apr.
2
A Machine Learning Model Accurately Predicts Ulcerative Colitis Activity at One Year in Patients Treated with Anti-Tumour Necrosis Factor α Agents.
Medicina (Kaunas). 2020 Nov 20;56(11):628. doi: 10.3390/medicina56110628.
3
Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases.
J Crohns Colitis. 2019 Aug 14;13(8):1012-1024. doi: 10.1093/ecco-jcc/jjz023.
本文引用的文献
1
Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases.
Inflamm Bowel Dis. 2015 Jul;21(7):1709-18. doi: 10.1097/MIB.0000000000000380.
2
Using a Treat-to-Target Management Strategy to Improve the Doctor-Patient Relationship in Inflammatory Bowel Disease.
Am J Gastroenterol. 2015 Sep;110(9):1252-6. doi: 10.1038/ajg.2015.86. Epub 2015 Apr 7.
3
Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission.
Inflamm Bowel Dis. 2014 Jun;20(6):1021-8. doi: 10.1097/MIB.0000000000000052.
4
Improving quality of care in inflammatory bowel disease: what changes can be made today?
J Crohns Colitis. 2014 Sep;8(9):919-26. doi: 10.1016/j.crohns.2014.02.022. Epub 2014 Apr 6.
5
A quality improvement project significantly increased the vaccination rate for immunosuppressed patients with IBD.
Inflamm Bowel Dis. 2013 Aug;19(9):1809-14. doi: 10.1097/MIB.0b013e31828c8512.
6
Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.
Gastroenterology. 2012 Jan;142(1):63-70.e5; quiz e31. doi: 10.1053/j.gastro.2011.09.034. Epub 2011 Sep 22.
7
Vaccinations and the Utilization of Immunosuppressive IBD Therapy.
Gastroenterol Hepatol (N Y). 2008 Dec;4(12):859-61.
8
Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses.
Am J Gastroenterol. 2006 Aug;101(8):1834-40. doi: 10.1111/j.1572-0241.2006.00646.x. Epub 2006 Jun 30.
9
Determinants of adult vaccination at inner-city health centers: a descriptive study.
BMC Fam Pract. 2006 Jan 10;7:2. doi: 10.1186/1471-2296-7-2.
10
Adult immunization programs in nontraditional settings: quality standards and guidance for program evaluation.
MMWR Recomm Rep. 2000 Mar 24;49(RR-1):1-13.
Zotero 插件